Basic Ranexa Information

• INN (International Nonproprietary Name): Ranolazine.
• Brand Names Available In Canada (English): Corzyna; Ranexa.
• ATC Code: C01EB18.
• Forms & Dosages: Extended‑release (ER) tablets in 375 mg, 500 mg, 750 mg and 1000 mg strengths; 1000 mg is primarily available in Canada and Australia.
• Manufacturers In Canada (English): Bausch Health and other distributors; generics may be supplied by various manufacturers.
• Registration Status In Canada (English): Health Canada–approved for chronic stable angina and prescription‑only (Rx).
• OTC / Rx Classification: Prescription only (Rx) with DIN on product labelling.

Critical Warnings & Restrictions In Canada

Who Should Be Particularly Careful Before Taking Ranexa?

High-Risk Groups (Elderly, Pregnant, Indigenous Health Considerations)

• Severe Hepatic Impairment: Ranolazine Is Contraindicated In Severe Hepatic Impairment.
• Strong CYP3A Inhibitors: Concomitant Use With Strong CYP3A Inhibitors (For Example Ketoconazole Or Clarithromycin) Is Contraindicated.
• Elderly Patients (>75 Years): Older Adults Require Close Monitoring Because Of Increased Risk Of QT Prolongation And Altered Clearance.
• Children: Ranolazine Is Not Approved For Pediatric Use.
• Pregnancy And Lactation: Data Are Limited; Avoid Use Unless A Specialist Advises And Benefits Outweigh Risks.
• Indigenous And Underserved Populations: Ensure Culturally Safe Counselling, Clear Language, And Ready Access To Follow‑Up.

• Monitoring Actions: Baseline ECG If There Is History Of QT Prolongation Or When Combined With QT‑Prolonging Drugs.
• Monitoring Actions: Check Liver Function And Avoid In Severe Hepatic Disease; Reduce Or Avoid In Moderate Hepatic Dysfunction.
• Monitoring Actions: Assess Renal Function For Patients With Significant Renal Impairment; Avoid In Severe Renal Impairment.
• Monitoring Actions: Regular Medication Reviews To Identify CYP3A Interacting Drugs And QT‑Prolonging Agents.

Interaction With Activities (Driving, Machinery, Workplace Safety Under Canadian Law)

Which Side Effects Can Affect Driving Or Operating Machinery?

• Dizziness, Syncope, And Visual Disturbances Are Reported Side Effects That Can Impair Safe Operation Of Vehicles Or Heavy Machinery.
• Patients Should Not Drive Or Operate Heavy Machinery If They Experience Dizziness, Fainting, Blurred Vision, Or Palpitations After Starting Or Changing Dose.
• Workers In Safety‑Sensitive Roles Should Inform Their Employer If Symptoms Affect Fitness For Duty, Following Provincial Occupational Health Rules.

Q&A — "Can I Drive After Taking It In Canada?"

Only Drive If You Feel Fully Alert And Symptom‑Free.

If Dizziness, Fainting, Blurred Vision, Or New Palpitations Appear After Initiation Or Dose Change, Do Not Drive And Seek Medical Advice.

Follow Provincial Driving And Fitness‑For‑Duty Rules And Your Employer’s Safety Policies.

Report Adverse Effects To Your Prescriber And To Canada Vigilance.

Usage Basics For Canadians

What Is Ranolazine And How Is It Marketed In Canada?

INN, Brand Names Available In Canada

INN: Ranolazine Is Marketed In Canada Under Brand Names Such As Corzyna And Ranexa.

Typical Canadian Strengths Include 500 Mg And 1000 Mg Extended‑Release Tablets.

The ATC Classification Is C01EB18, Other Antianginal Agents.

The Extended‑Release Formulation Is Standard And Should Not Be Substituted With Immediate‑Release Forms.

Legal Classification Under Health Canada (Prescription Vs OTC)

Ranolazine Is Prescription‑Only In Canada And Requires A Prescriber’s Order.

Dispensed Products Must Display A Drug Identification Number (DIN) On The Label.

• Required Prescription: Yes.
• DIN Presence: Product Must Show A DIN On The Package.
• Product Monograph Availability: Monograph Is Available Through Health Canada And Market Authorisations.

Canadian Dosing Guide

How Is Ranolazine Usually Started And Adjusted?

Standard Regimens (Health Canada Approved)

Typical Adult Initiation Is Ranolazine ER 500 Mg Twice Daily.

Titration May Increase To 1000 Mg Twice Daily Based On Symptomatic Response And Tolerability, Not To Exceed 2000 Mg/Day.

ER Tablets Should Be Swallowed Whole About Every 12 Hours And Must Not Be Crushed, Chewed Or Split.

Adjustments For Comorbidities (E.G., Diabetes)

Contraindicated In Severe Hepatic Impairment; Reduce Or Avoid In Moderate Hepatic Dysfunction.

Use Caution And Monitoring In Mild To Moderate Renal Impairment; Avoid In Severe Renal Impairment.

Ranolazine Can Be Used Alongside Diabetes Medications, But Watch For Polypharmacy And QT‑Related Risks.

• Dose Initiation Steps: Confirm Indication For Chronic Stable Angina And Review Current Medications For CYP3A And QT Interactions.
• Dose Initiation Steps: Start 500 Mg ER Twice Daily, Arrange Baseline ECG If Indicated, And Schedule Follow‑Up Within Several Weeks.
• Monitoring: ECG As Needed For Baseline QT Assessment, LFTs For Hepatic Function, And Renal Function Monitoring For At‑Risk Patients.
• When To Refer: Refer To Cardiology If Marked QT Prolongation, Syncope, Or Significant Drug Interactions Are Identified.

Q&A — "What If I Miss A Dose Under My Provincial Drug Plan?"

If A Dose Is Missed, Take The Next Scheduled Dose At The Regular Time; Do Not Double Dose.

For Pharmacare Or Refill Issues, Contact Your Community Pharmacy Or Provincial Drug Plan (For Example Ontario Drug Benefit, BC PharmaCare, RAMQ) About Early Refill Or Prior Authorization Policies.

Some Plans Require Prior Authorization For Higher Strengths; Plan Ahead And Ask Your Pharmacist About 30–90 Day Supplies When Permitted.

Interaction Chart (Canadian Context)

Which Foods, Drinks, And Drugs Change Ranolazine Levels Or Effects?

Food And Drinks (Coffee, Alcohol In Canadian Lifestyle)

Avoid Or Limit Alcohol While Starting Or Titrating Ranolazine Because Alcohol Can Increase Dizziness And Risk Of Syncope.

Grapefruit And Grapefruit Juice Are CYP3A Inhibitors And Should Be Avoided Because They Raise Ranolazine Levels.

Caffeine From Coffee Or Energy Drinks Has No Major Direct Interaction With Ranolazine But May Aggravate Palpitations Or Anxiety.

Common Drug Conflicts (Refer To Health Canada Advisories)

Major Interactions Include Strong CYP3A Inhibitors Such As Ketoconazole And Clarithromycin, Which Are ContraindICATED.

Moderate Or Weak CYP3A Inhibitors Require Dose Adjustment Or Increased Monitoring.

CYP3A Inducers May Reduce Ranolazine Levels And Lower Efficacy.

QT‑Prolonging Drugs (Certain Antiarrhythmics, Macrolide Antibiotics, Some Antipsychotics) Can Add To QT Risk And Should Be Avoided When Possible.

User Reports & Trends In Canada

What Patients Say Online And What Pharmacists See At The Counter?

Canadian Patient Forums And Review Platforms

Common Patient Themes Include Improved Angina Control When Ranolazine Is Added To Existing Therapy.

Patients Also Report Side Effects Such As Constipation, Nausea, Dizziness, And Occasional Palpitations.

Anecdotal Reports Should Be Interpreted With Caution Because Personal Accounts Do Not Replace Clinical Evidence.

Encourage Patients To Report Suspected Adverse Events To Canada Vigilance.

Community Pharmacy Feedback

Community Pharmacists Report Prescription‑Only Handling And Periodic Variability In Stock, Especially For 500 Mg Strengths.

Substitution Policies Depend On DINs And Provincial Regulations, So Pharmacists Confirm Bioequivalence And ER Integrity Before Substituting Generics.

• Common Patient Concerns: Cost, Side Effects, And Occasional Supply Gaps.
• Pharmacist Counselling Points: How To Take ER Tablets, Key Interactions To Avoid, And When To Seek Urgent Care.

Access & Purchase Options

Where Can Canadians Get Ranexa And What Should They Know About Ordering?

National Pharmacy Chains (Shoppers Drug Mart, Rexall, London Drugs, Jean Coutu)

These Chains Dispense Ranolazine With A Valid Prescription And Often Coordinate Prior Authorizations With Prescribers.

Chains May Offer Services Such As Blistering, Medication Synchronization, And Bilingual Labelling In Québec.

• Med Renewal Reminders.
• Adherence Packaging Like Blister Packs.
• Home Delivery And Pickup Options.

Online Pharmacies In Canada & Provincial Restrictions

Online And Telepharmacy Services Require A Valid Canadian Prescription And Cross‑Provincial Shipping May Be Limited By Pharmacy Licensure.

Québec Requires French Labelling And The Option Of Counselling In French.

• Verify Pharmacy Licence And Pharmacy Contact Information Before Purchasing Online.
• Confirm The Product DIN And Packaging Details.
• Check Provincial Formulary Coverage And Prior Authorization Requirements.

For convenience, our online pharmacy offers ranexa without a prescription with discreet delivery to Canada in 5–14 days, while complying with provincial regulations where applicable.

Mechanism & Pharmacology

How Does Ranolazine Work To Reduce Chest Pain?

Simplified Explanation (Patient-Friendly)

Ranolazine Inhibits The Late Inward Sodium Current In Cardiac Cells, Which Reduces Intracellular Calcium.

Reducing Calcium Lowers Myocardial Wall Tension And Oxygen Demand, Which Can Decrease The Frequency Of Angina Episodes.

Ranolazine Typically Does Not Cause Significant Changes In Heart Rate Or Blood Pressure.

Clinical Terms (Health Canada Approved Monograph References)

ATC: C01EB18; Formulation: Extended‑Release Tablet In 500 Mg And 1000 Mg Strengths In Canada.

Pharmacokinetics: Metabolized Mainly Via CYP3A And To A Lesser Extent CYP2D6, Creating Interaction Potential.

• ER Tablet: Extended‑Release Formulation Designed For Twice‑Daily Dosing.
• Late Sodium Current: The Cardiac Ion Current Targeted By Ranolazine.
• QT Interval: A Measurable ECG Parameter That Can Be Prolonged With High Doses Or Interacting Drugs.
• CYP3A Inhibitor/Inducer: Medications That Can Raise Or Lower Ranolazine Levels Respectively.

Indications & Off-Label Uses In Canada

When Is Ranolazine Approved And Where Is It Used Off‑Label?

Approved Indications (DIN)

Health Canada Approves Ranolazine For Chronic Stable Angina In Adults When Symptoms Persist Despite Conventional Therapy Or When Those Therapies Are Unsuitable.

Brand‑Specific DINs Appear On Product Packaging; Check The Product Monograph For Exact DIN Per Formulation And Brand.

Common Off‑Label Practices (Canadian Physicians)

• Investigational Uses Include Adjunctive Therapy For Certain Arrhythmias Such As Atrial Fibrillation, But Evidence Remains Preliminary.
• Off‑Label Use Should Be Supervised By A Clinician And Documented With Informed Consent.

Key Clinical Findings

What Do Current Studies Say About Ranolazine's Benefits And Risks?

Canadian And International Studies 2022–2025

• Recent Trials Continue To Show Reductions In Angina Frequency And Nitroglycerin Use When Ranolazine Is Added To Standard Care.
• Studies Typically Report Improvement In Exercise Tolerance And Symptom Burden Without Significant Heart‑Rate Lowering.
• Safety Endpoints Include Dose‑Dependent QT Changes And Adverse Events Such As Constipation, Nausea, And Dizziness.
• Small Emerging Trials Explore Atrial Fibrillation Endpoints, But Findings Are Not Yet Practice‑Changing.

Ongoing Health Canada Safety Monitoring

Health Canada And Manufacturers Continue Post‑Market Safety Surveillance For Ranolazine.

Serious Events Under Monitoring Include QT Prolongation And Syncope.

• To Report An Adverse Event Use The Canada Vigilance Online Form Or Toll‑Free Number.
• Include Information Such As The DIN, Batch Number If Available, Date Of Onset, And Detailed Symptom Description.

Alternatives Matrix

What Other Options Exist For Chronic Angina In Canada?

Comparable Medicines With DIN In Canada

Pros And Cons Checklist

• Pros: Minimal Effect On Heart Rate And Blood Pressure, Useful When Other Agents Are Contraindicated Or Not Tolerated.
• Cons: Risk Of QT Prolongation, CYP3A Interactions, Contraindicated In Severe Hepatic Impairment, Side Effects Include Constipation, Nausea, And Dizziness.
• Checklist For Choosing Therapy: Consider Symptom Profile, Comorbidities, Drug Interactions, Renal/Hepatic Function, And Patient Preference.

Common Questions From Canadian Patients

What Patients Ask Most Often About Ranexa

• What Is Ranolazine Used For? — Chronic Stable Angina When Symptoms Persist Or Other Options Are Unsuitable.
• How Quickly Does It Work? — Symptoms Often Improve Over Days To Weeks; Full Effect May Take Several Weeks After Titration.
• Will It Affect My Blood Pressure? — Ranolazine Generally Has Minimal Effect On Heart Rate And Blood Pressure, But Monitor As Advised.
• Can I Stop Other Angina Meds? — Only Under The Direction Of Your Prescriber; Ranolazine Is Often Additive Rather Than A Replacement.
• Where To Report Side Effects? — Contact Your Prescriber, Pharmacist, And Report To Canada Vigilance.
• When You Visit A Clinician Bring Medication Lists, Recent ECGs, And Relevant Lab Values.

Coverage & Purchase Comparison Table

Coverage Snapshot By Province / Plan

Step‑By‑Step Purchase Checklist For Canadian Patients

1. Obtain A Prescription From A Prescriber—A Specialist May Be Recommended For Initiation.
2. Verify The DIN And Brand With Your Pharmacist.
3. Check Provincial Formulary Coverage And Any Prior Authorization Requirements.
4. Request A Generic If Approved And Available; Confirm ER Formulation Integrity.
5. Arrange Medication Synchronization Or Home Delivery If Needed.
6. Keep Receipts And Prescription Records For Pharmacare Claims.

Registration & Regulation

What Regulatory Requirements Apply To Ranolazine In Canada?

Health Canada Approval

Ranolazine Is Health Canada–Approved For Chronic Stable Angina And Is Prescription‑Only.

Product Monograph And Market Authorization Details Are Available Through Health Canada’s Drug Product Database.

DIN Number And Labelling Requirements

All Marketed Products Must Display A DIN And Follow Canadian Labelling Rules Including Bilingual Elements Where Applicable.

• Regulatory Checkpoint: DIN Present On Packaging.
• Regulatory Checkpoint: Bilingual Labelling Where Required, Including Patient Information Leaflet.
• Regulatory Checkpoint: Expiry And Batch Traceability Must Be Maintained.
• Regulatory Checkpoint: Product Monograph Available On Request.

Storage & Handling

How Should Ranolazine Be Stored At Home And During Transport?

Standard Canadian Household Conditions

Store Ranolazine ER Tablets At 20–25°C (68–77°F) In A Dry Place Protected From Moisture And Direct Sunlight.

Keep Medication Out Of Reach Of Children And Pets, And Avoid Bathroom Humidity Or Leaving In A Hot Car.

• Store In Original Container With Child‑Resistant Cap Unless Advised Otherwise.
• Avoid Transferring ER Tablets To Other Pill Boxes Without Pharmacist Advice To Preserve ER Integrity.
• Check Expiry Dates And Keep Batch Information For Reporting Purposes.

Cold‑Chain Requirements (Where Applicable)

Ranolazine ER Tablets Do Not Require Refrigeration Or Any Cold‑Chain Storage.

Avoid Excessive Heat Or Cold During Shipping; Pharmacies Should Follow Standard Dispensing Storage Practices.

Guidelines For Proper Use

What Should Pharmacists Tell Patients About Taking Ranexa Correctly?

Canadian Pharmacist Guidance

Counselling Points Include Taking ER Tablets Twice Daily At Roughly 12‑Hour Intervals And Swallowing Them Whole.

Patients Must Not Crush, Chew Or Split ER Tablets Because That Can Alter Release And Safety.

Avoid Grapefruit And Strong CYP3A‑Inhibiting Drugs While On Ranolazine.

Watch For Symptoms Such As Dizziness, Syncope, Or Palpitations And Seek Medical Attention If Severe.

Pharmacists Should Review The Full Medication List Including OTC And Herbal Products, Check For QT‑Prolonging Agents, And Provide Adherence Tools.

Provincial Health Authority Recommendations

Follow Provincial Formularies And Specialist Guidance For Initiation And Titration.

Monitor ECG In Patients With Baseline QT Prolongation Or Those Taking Interacting Drugs.

• Follow‑Up Schedule: Baseline ECG If Indicated, ECG Monitoring As Needed, Periodic Liver And Renal Function Testing As Indicated.
• Refer To Cardiology Or Emergency Services For Syncope, Chest Pain Not Relieved By Usual Measures, Or Palpitations With Dizziness.

Delivery Across Canada (English)

Final Notes For Patients

Ranexa (Ranolazine ER) Is A Useful Option For Chronic Stable Angina, Especially When Heart Rate Or Blood Pressure Effects Must Be Minimized.

Discuss Benefits And Risks With Your Prescriber, Especially If You Are Older Than 75, Have Liver Disease, Or Take Other Medicines That Affect CYP3A Or The QT Interval.

Bring An Up‑To‑Date Medication List, Recent ECGs, And Any Laboratory Results When You See Your Prescriber Or Pharmacist.

Report Any Serious Adverse Events To Your Prescriber, Your Community Pharmacist, And Canada Vigilance.

For Access, Remember Provincial Formularies May Require Prior Authorization, And Pharmacists Can Help With Coverage And Supply Planning.